Last reviewed · How we verify

NCT04352036: COVER

Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)

Recruiting now Last updated 5 September 2025
What this trial tests

trial testing no interventional study in Acute Hidrosadenitis in 465 participants. Currently enrolling.

Timeline
4 January 2022
Primary endpoint
20 February 2030
20 February 2030

Quick facts

Lead sponsorNantes University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment465
Start date4 January 2022
Primary completion20 February 2030
Estimated completion20 February 2030
Sites13 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

Eligibility, any sex, with Acute Hidrosadenitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. Indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of no interventional study

Trials testing the same drug.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04352036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing